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Proline-Rich Peptides with Improved Antimicrobial Activity
against E. coli, K. Pneumoniae, and A. Baumannii
Mario Mardirossian,[a] Riccardo Sola,[a] Bertrand Beckert,[b] Dominic W. P. Collis,[c]
Adriana Di Stasi,[a] Federica Armas,[a] Kai Hilpert,[d] Daniel N. Wilson,*[b] and Marco Scocchi*[a]
Proline-rich antimicrobial peptides (PrAMPs) are promising
agents to combat multi-drug resistant pathogens due to a high
antimicrobial activity, yet low cytotoxicity. A library of deriva-
tives of the PrAMP Bac5(1–17) was synthesized and screened to
identify which residues are relevant for its activity. In this way,
we discovered that two central motifs -PIRXP- cannot be
modified, while residues at N- and C- termini tolerated some
variations. We found five Bac5(1–17) derivatives bearing 1–5
substitutions, with an increased number of arginine and/or
tryptophan residues, exhibiting improved antimicrobial activity
and broader spectrum of activity while retaining low cytotox-
icity toward eukaryotic cells. Transcription/translation and
bacterial membrane permeabilization assays showed that these
new derivatives still retained the ability to strongly inhibit
bacterial protein synthesis, but also acquired permeabilizing
activity to different degrees. These new Bac5(1–17) derivatives
therefore show a dual mode of action which could hinder the
selection of bacterial resistance against these molecules.
Introduction
Multi-drug resistant (MDR) pathogens are a concerning health
problem worldwide that will seriously compromise many
medical procedures, from routine to life-saving treatments.[1]
Thus, the demand for novel antibacterial drugs with new mode
of action is urgent. In this context, antimicrobial peptides
(AMPs) have received considerable attention as potential lead
compounds for the development of new antibiotics, however,
they are often limited by cytotoxic activity and possible non-
specific or even undesired interactions within the host’s body.[2]
By contrast, the subclass of proline-rich antimicrobial peptides
(PrAMPs) has potent antimicrobial activity against some of the
most alarming bacterial species for MDR infections, such as
Klebsiella pneumoniae, Acinetobacter baumannii and Escherichia
coli[1,3] and, at the same time, they are generally characterized
by a low cytotoxic profile.[3] One reason for this might be that,
unlike many AMPs, PrAMPs do not kill bacteria by damaging
their membranes,[4] but rather enter the bacterial cytosol using
primarily the inner membrane transporters SbmA, and to a
minor extent the MdtM complex.[5] Once inside the bacterial
cell, many PrAMPs cause a lethal inhibition of protein synthesis
by targeting mainly the ribosome.[6] Derivatives of the mamma-
lian PrAMPs Bac7 and Tur1 A, as well as of the insect PrAMPs
oncocin, pyrrhocoricin, metalnikowin and apdidaecin, share
overlapping binding sites located within the exit tunnel of the
ribosome.[7] These PrAMPs inhibit protein synthesis either by
blocking the binding of the aminoacyl-tRNA to the peptidyl-
transferase center during translation elongation,[7c,8] or by
trapping the decoding release factors on the ribosome during
the translation termination phase.[7a,9]
Many studies reduced the length of PrAMPs to lower the
cost of synthesis while maintaining their antimicrobial
properties.[10] Other studies have characterized fragments,
derivatives or dendrimers of PrAMPs by often modifying their
amino acid sequence by one or few residues. In addition, the
rational design of new PrAMPs was reported (see for
example[11]). Synthetic peptide arrays on cellulose support also
known as SPOT synthesis (see[12]) allows the easy production of
peptide libraries and was successfully applied to insect-derived
PrAMPs to broaden their spectrum of activity and improve their
antimicrobial properties compared with their native
molecules.[13]
Bac5 is a bovine proline-rich cathelicidin, whose mode of
action was recently described.[6f] Bac5 fragments inhibit bacte-
rial protein synthesis[6f] and are mostly active against Gram-
negative pathogens,[14] including E. coli, A. baumannii and
Salmonella enterica ser. typhimurium.[11b,14] The N-terminal 1–17
fragment of Bac5 retained antimicrobial activity and the same
overall mechanism of action to inhibit protein synthesis as other
PrAMPs.[11b] However, because of the lack of homology between
Bac5 and other PrAMPs, as well as the absence of a structure of
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Bac5 on the ribosome, it has remained unclear which residues
of Bac5 are critical for its translational inhibitory activity.
Here we have prepared three consecutive substitution
libraries of Bac5(1-17), a Bac5 fragment with a length compat-
ible with the SPOT-synthesis. The Bac5(1-17) peptide was
systematically modified to identify key residues for antimicro-
bial activity. Moreover, by single and multiple residues sub-
stitutions, we identified peptides with improved antimicrobial
activity and broader spectrum of action due to a moderate
membrane permeabilizing effect.
Results
Identification of Bac5(1–17) Residues Essential for
Antimicrobial Activity
To identify key residues for the antimicrobial activity of Bac5(1–
17), an alanine-scan was performed. The seventeen Bac5(1–17)
derivatives were tested for their capability to inhibit protein
synthesis in vitro using coupled transcription/translation assays
[6a,6f, 7c, 8a,8b,11b] as well as to inhibit the growth of E. coli
cells using minimal inhibitory concentration (MIC) assays in
Müller-Hinton broth (MHB) (Figure 1). Ten out of 17 alanine-
substituted Bac5(1–17) derivatives did not display any antimi-
crobial activity (MIC>64 μM). These included alanine-substitu-
tions in almost all the positions of the two repeats of the
-PIRXP-, whereas the N- and C-terminal residues were more
tolerant to substitutions as seen by an MIC comparable to the
wild type Bac5(1–17). As expected, a scrambled Bac5(1–17)
control peptide displayed no antimicrobial activity (MIC>
64 μM) and did not inhibit protein synthesis in vitro. Generally,
the trend of protein synthesis inhibition of the Bac5(1–17)
derivatives paralleled the activity in the MIC assay (Figure 1),
e.g. the wild type Bac5(1–17) exhibited 50% inhibition at 10 μM
and nearly complete inhibition at 100 μM, similarly to the N-
and C-terminal substituted Bac5(1–17) derivatives. By contrast,
alanine-substitutions in the PIRXP repeats generated peptides
that had little if any inhibitory activity at 10 μM and required
100 μM to observe inhibition. These findings suggest that the
core PIRXP repeats are critical for interaction of Bac5(1–17) with
the ribosome.
SPOT-Synthesis Screen for Bac5(1–17) Derivatives with
Improved Antimicrobial Activity
To identify Bac5(1–17) derivatives with improved activity, a
SPOT-synthesis was performed where further substitutions were
introduced individually at each and every position of the Bac5
(1–17) sequence. Specifically, we inserted residues with distinct
chemical and physical characteristics, such as Gly (G, no side
chain, small), Ser (S, small, polar), Arg (R, large, positively
charged, hydrophilic), Pro (P, restricts conformation), Glu (E,
medium, negatively charged, hydrophilic), Phe (F, large,
aromatic, one ring, hydrophobic) and Trp (W, large, aromatic,
two rings, hydrophobic) in every position of the Bac5(1–17)
sequence, generating 122 derivatives. The MIC was then
determined using E. coli BW25113 in MHB to assess whether the
Bac5 derivatives had altered antimicrobial activities compared
to the wild type and scrambled Bac5(1–17) peptide controls
(Table 1). Similar to the alanine-scanning, glycine substitutions
within the core of the peptide lead to a loss of antimicrobial
activity, whereas substitutions at the N- and C-termini were
better tolerated. By contrast, substitutions of Glu, Pro and Ser
led to dramatic loss of the antimicrobial activity (MIC 64 μM or
greater) regardless of the position, with the single exception of
P4S that had an MIC (16 μM) comparable with the wild type.
While substitutions with Phe, Trp and Arg were better tolerated,
overall only 11 of the 122 derivatives actually displayed
stronger antimicrobial activity than the wild type. These
included P4 substitutions with Trp, Phe, Arg as well as Gly. In
addition, Trp at positions 2, 6, 15, 16 and 17 as well as Arg at
positions 9 and 17 led to improved MIC values. Thus, in total,
Figure 1. In vitro transcription/translation and MIC assays monitoring inhibitory activity of Bac5(1–17) and its derivatives. Transcription/translation
reactions (bar graph) were performed in presence of 10 μM (light gray) and 100 μM (dark gray) peptide. The luminescence (RLU%) of the translated luciferase
(left hand Y-axis) was normalized using the untreated controls and reported as average and standard deviation of at least three independent experiments.
The peptide sequence is given on the X-axis, and the values above each residue refer to the peptide carrying the alanine substitution in that position. The
boxed sequences highlight the two PIRXP sequences. The minimal inhibitory concentration (MIC) for the Bac5(1–17) derivatives (line graph with black
diamonds) is shown with tested concentrations indicated on right hand Y-axis. Unmodified wild type (wt) and scrambled (scr) Bac5(1–17) peptides were used
as controls for both MIC and transcription-translation assays.
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substitutions at seven distinct positions (2, 4, 6, 9 and 15–17)
led to MIC improvements. Interestingly, three of the seven
positions were prolines (P4, P9 and P17), indicating that prolines
at these positions are not crucial for the antimicrobial activity of
the Bac5(1-17) derivatives.
Antimicrobial Activity and Cytotoxicity of Bac5(1–17)
Multi-Substituted Derivatives
The single amino acid substitutions improving the antimicrobial
properties of Bac5(1-17) were then combined to design new
peptides (Bac5 peptides 265 to 296 in Table 2). This new
peptide library was first screened for antibacterial activity
against E. coli BW25113 and then assayed by a tetrazolium salt
assay (MTT) for cytotoxicity toward the human lymphocytic
leukaemia cell line MEC-1. A two-fold increase in MIC values
was observed for some of the same peptides displayed in
Table 1 (from 260 to 264) due to the intrinsic variability of
peptide purity among the different SPOT-syntheses. However,
with the exception of the peptide 262, all of these derivatives
were equally or more active than the wild type Bac5(1–17) with
many of them displaying MIC values of 4 μM. Generally, the
antimicrobial activity increased with the number of substitu-
tions, such that the single substituted peptides displayed a
median MIC of 16 μM, di- and tri-substituted peptides 8 μM,
and tetra-substituted peptides 4 μM. Although three penta-
substituted peptides displayed a MIC of 4 μM (Bac5-derivatives
291, 293, 294), additional substitutions often led to a worse MIC
as seen when comparing 281 with 290 or 282 with 292 (MIC 4
increased to 8 μM) as well as 289 with 296 (MIC 8 increased to
16 μM). Next, the cytotoxicity of the peptide library was
assessed by monitoring the viability of human lymphocytic
leukaemia cells (MEC-1) treated with 32 μM of each peptide
(Table 2). Only two Bac5 peptides (273 and 293) displayed
severe cytotoxicity, reducing the viability of treated cells by
32% and 41%, respectively.
Five of the screened peptides were then further character-
ised. They were representative of a progressively increasing
number of substitutions (from 1 to 5), displaying low MIC values
and high biocompatibility towards eukaryotic cells (viability %).
Table 1. MIC values (μM) of the native Bac5(1-17), of its substitution
variants and of a scrambled form against E. coli BW25113.
Grey shades highlight substitutions improving antimicrobial activity
compared to the native Bac5(1-17); [a] Bac5(1-17) sequence and position
numbers; [b] Bac5(1–17) wild-type; [c] Bac5(1-17) scrambled; [d] The Ala-scan
MIC values from Figure 1 are also included in this table for comparison.
Results are the median of at least three independent experiments (n�3).
The scrambled peptide (scr) sequence was: FPIRYRPFRRPPRPIPP.
Table 2. MIC (μM) values measured against E. coli BW25113 and effects of 32 μM of the second generation Bac5(1-17) derivatives on MEC-1 cell viability
(Viab, % of untreated controls).
Code Sequence N°(+) MIC Viab% Code Sequence N°(+) MIC Viab%
wt RFRPPIRRPPIRPPFYP +5 32 108 277 RWRRPIRRRPIRPPFYP +7 8 99
258 RFRPPIRRPPIRPPFYR +6 8 95 278 RWRWPIRRPPIRPPFYR +6 4 86
259 RFRRPIRRRPIRPPFYP +7 8 105 279 RFRWPIRRRPIRPPFYR +7 8 84
260 RWRPPIRRPPIRPPFYP +5 16 81 280 RFRWPIRRRPIRPPFYW +6 4 78
261 RFRWPIRRPPIRPPFYP +5 8 82 281 RWRRPIRRRPIRPPFYW +7 4 81
262 RFRPPIRRPPIRPPWYP +5 32 81 282 RWRRPIRRRPIRPPFYR +8 4 99
263 RFRPPIRRPPIRPPFWP +5 16 81 283 RWRRPIRRRPIRPPWYP +7 4 91
264 RFRPPIRRPPIRPPFYW +5 16 95 284 RFRWPIRRRPIRPPWYR +6 4 72
265 RFRRPIRRPPIRPPFYR +7 8 91 285 RFRRPIRRRPIRPPFWR +8 8 90
266 RFRRPIRRRPIRPPFYR +8 16 87 286 RFRWPIRRRPIRPPFWR +7 4 80
267 RWRPPIRRPPIRPPWYP +5 16 75 287 RFRRPIRRRPIRPPWYR +8 8 95
268 RFRWPIRRPPIRPPWYP +5 8 93 288 RRRRPIRRRPIRPPFYR +9 16 102
269 RWRWPIRRPPIRPPFYP +5 8 92 289 RRRRPIRRRPIRPPWYP +8 8 95
270 RWRWPIRRPPIRPPWYP +5 8 90 290 RWRRPIRRRPIRPPWYR +8 8 91
271 RFRWPIRRRPIRPPFYP +6 4 98 291 RWRRPIRRRPIRPPFWR +8 4 96
272 RFRWPIRRPPIRPPFYR +6 4 102 292 RWRRPWRRRPIRPPFYR +8 8 78
273 RFRRPIRRPPIRPPWYP +6 12 68 293 RWRWPIRRRPIRPPWYR +7 4 59
274 RWRRPIRRPPIRPPFYP +6 8 84 294 RWRWPIRRRPIRPPFWR +7 4 73
275 RWRRPIRRPPIRPPFYR +7 8 89 295 RRRRPWRRRPIRPPFYW +8 8 77
276 RWRRPIRRPPIRPPWYP +6 8 83 296 RRRRPIRRRPIRPPWYR +9 16 95
Results of the MIC and cell viability assays are reported as the median or the average, respectively, of at least 3 independent experiments N° indicates the
number of charges. The sequences of the peptides selected for synthesis on resin are in bold.
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The mono-substituted peptide 258 was selected so as to
include an intermediate substitution state linking the wild type
Bac5(1-17) and di-substituted peptide 272 (containing P4W and
P17R), which was the most promising di-substitute derivative
(Table 2). The peptide 278 was selected among the tri-
substituted derivatives because of its lower MIC value. Regard-
ing the tetra-substituted peptides, the 281 was preferred over
282 to evaluate the effects of a C-terminal Trp. Lastly, the
peptide 291 had the lowest MIC value and did not display any
cytotoxicity.
Despite SPOT synthesis provides a powerful initial screening
tool, the produced peptides are un-purified. For this reason the
five selected Bac5(1-17) derivatives (258, 272, 279, 281 and 291),
as well as the wild-type Bac5(1–17), were singularly re-
synthesized by resin-based synthesis at �95% purity. For all
the subsequent experiments, only highly purified peptides were
used.
Inhibition of in vitro Transcription/Translation by Five
Selected Bac5 (1–17) Derivatives
The ability of the five selected Bac5(1–17) derivatives (258, 272,
279, 281 and 291) to inhibit protein synthesis was then assessed
using an in vitro transcription/translation assay based on E. coli
lysates, and compared with that of the wild-type peptide. Three
of the derivatives (258, 272 and 278) displayed inhibitory
activity comparable with that of the wild type Bac5(1-17)
peptide, with a near complete inhibition of translation occur-
ring at 10 μM (see Figure 2). Importantly, since the antibacterial
activities of these peptides were stronger than the wild type
Bac5(1–17), this suggests that the improved MIC values arising
from the amino acid substitutions is not due to an improved
interaction with the ribosome. Indeed, this is emphasized by
the 281 and 291 peptides which had superior MIC values (4 μM)
and yet were respectively worse and slightly worse inhibitors
than then wild type Bac5(1–17) in the transcription/translation
assay (Figure 2). Collectively, these findings suggest that the
improved antimicrobial activity of the substituted Bac5(1–17)
derivatives compared to the wild type Bac5(1-17) peptide
(observed in Table 2) is not due to an improved ability to bind
to ribosomes and inhibit translation (Figure 2).
Membrane-Permeabilizing Activity of Five Selected Bac5(1–
17) Derivatives
The lack of an improved inhibitory activity of the Bac5(1–17)
derivatives in the transcription/translation system indicates that
their improved antibacterial activity is due to another mode of
action. Given the number of positively charged arginine and
tryptophan substitutions introduced into these peptides, an
explanation for the improved activity could be that these
peptides acquired a membrane-permeabilizing ability. To test
this hypothesis, the membrane integrity of E. coli cells was
assessed in the presence of the selected peptides using flow
cytometry measuring the fluorescence of propidium iodide (PI)
uptake by the permeabilized bacterial cells. To evaluate how
many bacteria were permeabilized by the peptides, the
percentage of the bacterial population becoming positive to PI
Figure 2. Inhibition of in vitro transcription/translation by selected Bac5(1–17) derivatives. Increasing concentrations of peptides were added to an E. coli
lysate-based transcription/translation reaction. Luminescence of the firefly luciferase reporter protein produced after 60 min is presented as relative
luminescence compared to control samples, which lacked peptide and was normalized as 100%. Error bars represent the standard deviation calculated on the
average of at least 5 independent experiments (n=5). **=p-value <0,01 versus the wt peptide (Student t-test).
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after exposure to the derivatives was calculated (Figure 3A).
Afterwards, the extent of the membrane damage was estimated
by measuring the intensity of fluorescence associated with the
permeabilized cells (Figure 3B). As a control, the wild-type Bac5
(1–17) did not display any membrane damaging activity, which
is in agreement with the literature and its known mode of
action (Figure 3) [11b]. The Bac5 peptides 258, 272 and 278
displayed no permeabilizing effect at 4 μM, however, some
membrane-destabilizing activity was observed for 272 and 278
at higher (16 μM) concentrations (Figure 3). By contrast, 4 μM of
the 281 or 291 peptides was sufficient to permeabilize 100% of
bacterial cells, to a similar extent as 1 μM colistin, the positive
control used for permeabilizing activity [15]. However, it should
be noted that even the highest fluorescence intensities
measured by the most permeabilizing peptides at 16 μM were
still only 20% of that observed for bacteria treated with colistin
used at 16-fold lower concentrations (1 μM) (Figure 3B). These
results show that the 272 and 278 peptides gained a moderate
degree of membrane permeabilization activity, observable only
at high concentrations, whereas the 281 and 291 peptides
exerted permeabilization activity even at low (yet bactericidal)
concentrations. By contrast, the wild type Bac5(1–17) and 258
peptide lacked any permeabilizing activity, even at high peptide
concentrations. Collectively, these results suggest that im-
proved antimicrobial activity of the 281 and 291 peptides
compared to wild type Bac5(1–17) may result from their newly
acquired ability to destabilize the bacterial membrane.
Influence of SbmA and Evaluation of the Activity Spectrum of
Bac5(1-17) Derivatives
Since the membrane integrity assays indicated that the 281 and
291, and to a lesser extent 272 and 278 peptides, exhibited
permeabilizing activity, whereas the 258 peptide did not, we
were interested in assessing the influence of the SbmA trans-
porter on the antimicrobial activity of these peptides. To do
this, MIC assays were performed using the E. coli BW25113
parental strain as well as the BW25113ΔsbmA strain lacking this
inner membrane transporter (Table 3). As expected, Bac5(1-17)
displayed antimicrobial activity (MIC 16 μM) against the paren-
tal strain, but not the BW25113ΔsbmA strain (MIC >64 μM),
consistent with the essential role of SbmA for the internalization
of this peptide [5a]. By contrast, the 272, 278, 281 and 291
Figure 3. Flow cytometric evaluation of E. coli BW25113 membranes permeabilization. Propidium-iodide uptake assay was performed after 30 min
incubation in the presence of 4 μM and 16 μM of peptides. (A) The percentage of permeabilized cell in the bacterial population and (B) the average
fluorescence of permeabilized bacteria were assessed. 1 μM of the lytic antibiotic colistin (Colist.) was used as a positive control of permeabilization. In the
untreated control (Untr.) bacteria were treated with sterile water. Average and standard deviation of three independent experiments. *=p-value <0.05 versus
the wt peptide (Student t-test).
Table 3. MIC and MBC of the native Bac5(1–17) (wt) and selected Bac5-derivatives on pathogenic and reference bacterial strains.
MIC (μM) MBC (μM)
Bacteria wt 258 272 278 281 291 wt 258 272 278 281 291
E. coli BW25113 16 8 4 2 2 2 >64 64 8 4 2 8
E. coli BW25113ΔsbmA >64 64 8 8 4 4 >64 >64 16 8 8 8
K. pneumoniae ATCC 700603 >64 >64 24 16 64 4 >64 >64 >64 48 >64 >64
A. baumannii ATCC 19606 >64 64 8 4 2 8 >64 64 16 8 8 16
P. aeruginosa ATCC 27853 >64 >64 64 16 32 32 >64 >64 64 64 48 >64
S. aureus ATCC 25923 >64 >64 >64 >64 32 64 >64 >64 >64 >64 32 64
E. coli EURL-VTEC A07 EPEC:O111 16 8 2 1 2 2 – – – – – –
E. coli EURL-VTEC C07 STEC:O157 >64 >64 8 8 2 2 – – – – – –
E. coli SSI-NN14 ETEC 2 2 1 1 2 1 – – – – – –
E. coli EA22 ETEC 2 2 1 1 2 1 – – – – – –
E. coli SSI-OO15 EIEC 16 4 1 1 1 1 – – – – – –
E. coli C679-12 EAEC:0104 16 8 2 2 2 1 – – – – – –
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peptides all displayed excellent activity against both the
parental and ΔsbmA strain, with only a 2-fold activity reduction
being observed in the absence of the transporter (Table 3). This
data indicates a mechanism of action that does not require the
use of the SbmA transporter. The 258 peptide displayed
antimicrobial activity (MIC 8 μM) against the parental strain, but
was also ineffective against the ΔsbmA strain (MIC 64 μM),
consistent with the lack of permeabilization activity (Figure 3).
Overall, the highly purified derivatives 278, 281 and 291
displayed 2 fold lower MIC against E. coli BW25113 (Table 3)
with respect to the values reported in Table 2 and referred to
the same molecules obtained by SPOT synthesis. This difference
is most likely due to the lower degree of purity achievable using
the latter technique.
The five selected Bac5(1–17) derivatives were further tested
against reference and pathogenic strains of E. coli as well as
ATCC reference strains of clinically relevant Gram-negative
pathogens (Table 3) and the Gram-positive S. aureus. Remark-
ably, all peptides with substitutions possessed increased
antibacterial activity against one or more strains among the
pathogenic bacteria tested. They were highly effective against
four different virotypes of E. coli isolates from patients (Table 3),
in most cases showing MIC values (1–2 μM) comparable or
lower than that of the reference strain BW25113. Remarkably,
the Bac5 272, 278 and 291 derivatives acquired antimicrobial
activity against K. pneumoniae and A. baumannii strains with
MIC values ranging from 4 to 24 μM, while strikingly 281 was
highly active against A. baumannii (MIC 4 μM). P. aeruginosa
and S. aureus were intrinsically resistant to the native Bac5(1–
17). However, P. aeruginosa was moderately sensitive (MIC
16 μM) to the 278 peptide and weakly sensitive (MIC 32–64 μM)
to 272, 281 and 291 peptides. On the other hand, S. aureus
showed weak sensitivity to 281 and 291 (MIC 32–64 μM)
(Table 3). By contrast, the 258 peptide displayed no improve-
ment in antimicrobial activity against these strains, suggesting
that the broader spectrum of activity displayed by the other
peptides is likely due to their newly acquired membrane-
permeabilizing activity. Interestingly, the improvement of
antimicrobial activity (reduction of the MIC) often correlated
with a reduction in the MBC.
Cytotoxicity of Bac5(1–17) Derivatives on MEC-1 Cells
Given the increased membrane-permeabilizing activity and
broader spectrum of activity observed by the Bac7(1–17)
derivatives, concerns were raised as to the possibility of a
corresponding increase in the cytotoxicity of the peptides. To
address this, the viability of MEC-1 cells was assessed in the
presence of high concentrations (16–64 μM) of each peptide. At
the highest concentration tested (64 μM), only the 281 peptide
remarkably reduced cell viability, causing an 80% reduction in
viability with respect to the untreated control after 24 h
incubation (Figure 4). The other peptides, including the wild
type, did not decrease the viability of the cells by more than
20–30%, compared to the untreated control. Interestingly, the
291 peptide, which like the 281 peptide, displayed high levels
of membrane permeabilizing activity, did not reduce cell
viability at 32 μM, and exhibited only mild toxic effects
(reduction of 5% of the cell viability) even at 64 μM.
Discussion
Here we identified the amino acid residues of the PrAMP Bac5
(1–17) that are crucial for the inhibition of the bacterial protein
Figure 4. Toxicity evaluation by MTT assay of selected Bac5(1–17) derivatives toward the human cell line MEC-1. The viability of cells treated with peptides
is reported in relation to the 100% viability of a control receiving only sterile water. Most of the peptides at 32 μM display a little decreased cell viability
values with respect to those reported in Table 2. Little discrepancies are most likely due to the higher purity of the peptides used in this experiment compared
to those used in the assays reported in table 2 (SPOT-synthesis). Error bars are the standard deviations calculated on the average of 3 independent
experiments performed in duplicate (n=6).
Full Papers
6ChemMedChem 2019, 14, 1–10 www.chemmedchem.org © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Mittwoch, 13.11.2019
1999 / 151641 [S. 6/10] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
synthesis and viability against E. coli. Then, we combined
selected residue substitutions obtaining Bac5(1–17) derivatives
with increased antibacterial potency and displaying broader
spectrum of activities.
Firstly, we showed that Bac5(1–17) does not tolerate single
residue substitutions in the two -PIRR/PP- repeats of the central
regions (residues 5–14) which often reduced or abolished the
antimicrobial activity of Bac5(1–17) (see Table 1). Substitutions
in the   PIRR/PP  sequences impaired in parallel also the
inhibition of the protein synthesis, indicating that the central
moiety of Bac5(1–17) is crucial for its interaction with the E. coli
ribosome and therefore for the antimicrobial activity. This
region roughly overlaps with the PR-rich region, shared by
many PrAMPs (Figure 5), which targets the exit tunnel of the
bacterial ribosome.[7b] Ala-scans performed on pyrrhocoricin[15]
and oncocin O1[16] indicated that residues present in this
conserved region are important or crucial for their antimicrobial
activity. Mutations I6W and P9R are the only substitutions
falling in this Bac5(1–17) region which did not cause loss of
activity (Table 1). P9R substitution makes Bac5(1–17) more
similar to the other PrAMPs showing a conserved arginine in
that position (Figure 5), I6W introduces a sterically bulky group
in a position corresponding to a tyrosine or arginine in the
other AMPs. Structural studies will be necessary to understand
the meaning of these modifications.
We showed previously that the shortening of the Bac5(1–
17) sequence affected its antimicrobial activity[11b,14] leading to
the assumption that the N- and C-termini were non-modifiable
without a dramatic loss of activity. However, here we found
that the ends of Bac5(1–17) sequence can be changed, some-
times even improving the antibacterial activity. Generally,
residue substitutions with R or W in the peptide termini
fostered the antibacterial potency of Bac5(1–17). Their simulta-
neous introduction into new peptides sometimes resulted in
further improvements of the antimicrobial activity. It is worth
noting that these improvements are most likely due to a gain in
the capability of the PrAMPs to affect membrane stability. This
effect increased progressively from the non-permeabilizing
Bac5(1–17) and B5 peptide 258, to the more permeabilizing and
more potent 281 and 291 derivatives (Table 3, Figure 3). The
peptides 272 and 278 fell in-between, acquiring membrane-
destabilizing activity in the range of concentrations tested. In
each case, the membrane-destabilizing effects of the more
effective 281 and 291 peptides are far from that exhibited by
the peptide antibiotics colistin, used as a reference for a potent
lytic antibacterial compound.[17] However this could be sufficient
to promote the efflux of ions and metabolites from the bacterial
cells negatively affecting the viability of bacteria.
Interestingly, although these peptides gained a moderate
activity on the membrane, they also maintained an unchanged
efficacy in targeting the bacterial protein synthesis. Bac5
peptide 281 was the only peptide that exhibited a significantly
decreased inhibitory effect on the protein synthesis, maintain-
ing however a relevant antimicrobial potency, that mainly relies
on its permeability mechanism. Apart from this exception, the
other four peptides might exert a dual mode of action, since
they could both cross the bacterial membrane, as suggested by
their reduced dependency on the bacterial transporter SbmA,
efficiently inhibiting protein synthesis and destabilizing at the
same time the bacterial membrane. The latter effect is more
relevant at high concentrations. A dual mode of action
(membrane destabilization and protein synthesis inhibition)
would represent an added value for the antimicrobial potential
of these peptides because it makes the selection of bacterial
resistance more difficult.
The five selected Bac5(1-17) derivatives also display a wider
spectrum of activity, becoming active against pathogenic
strains of A. baumanni, K. pneumoniae and E. coli. The
antibacterial activity was tested by using the antibiotic-
reference medium MHB without any dilution and no other
“poor” media as often reported in the literature.[18] This was
done to increase the robustness of these results but also to use
a standardized method, to make the comparison with other
antimicrobials possible. Bac5 derivatives are likely to exploit the
SbmA homologue of E. coli to enter bacterial cells of A.
baumanni and K. pneumoniae[7b] but this is not sufficient to
explain their activity, albeit weak, against P. aeruginosa and S.
aureus, both lacking SbmA. A membrane-destabilizing activity
that provides SbmA-independent mechanism has already been
described in P. aeruginosa for the mammalian PrAMP Bac7(1-35)
and for the insect-derived Apideaecins.[19] This would be in
agreement with the membrane-destabilizing effect observed in
this study. Further studies will be necessary to elucidate the
mode of action of these peptides on bacterial species other
than E. coli.
The improvement in antimicrobial potency and activity
spectrum of Bac5(1-17) derivatives is not followed by a parallel
increase in toxicity towards eukaryotic cells. Toxicity was only
observed at concentrations well above the MIC and MBC values
for 4 out of the 5 peptides. The peptide 281 was the only one
displaying considerable toxicity and this may be due to its
distinct mode of action to permeabilize membranes, and hence
to be less selective for bacteria. By contrast, the 291 peptide
was not only potent, but also non-toxic, even at 64 μM, and
thus could be promising as a lead compound for development
of new drugs.
Figure 5. Sequence alignment between Bac5(1–17) and other ribosome-
targeting PrAMPs. In bold are the amino acids conserved at least in four
different PrAMPs. The grey box indicates the PIRR/PP regions of Bac5(1–17).
D-amino acids in Onc112 are indicated by lowercase letters.
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Conclusions
In conclusion, we identified Bac5(1–17) derivatives that com-
bine a broad spectrum of activity and a low MIC against
relevant pathogens with low cytotoxicity. These peptides are as
effective against E. coli and other pathogens as the most potent
known Bac5 fragment, i. e. the Bac5(1–25),[11b] but have the
advantage of being shorter, having a wider activity spectrum as
well as a dual mechanism of action. The optimization of
mammalian PrAMPs by SPOT-synthesis provided small, less
expensive and more effective molecules to be developed as
second-generation antibiotics.
Experimental Section
Peptide Synthesis
Peptides libraries were prepared by SPOT-synthesis using a Multi-
Pep RSI peptide synthesizer (Intavis, Germany), by adapting
reported protocols.[12] The cellulose membrane (10 cm×15 cm) was
functionalised overnight in 0.2 M Fmoc-Gly-OH (Aldrich), 0.24 M
N,N’-diisopropylcarbodiimide (DIC, Fluka) and 0.4 M N-meth-
ylimidazole (NMI, Aldrich) in dimethylformamide (DMF, VWR). Then,
the glycine was de-protected in 20% piperidine (v/v, Acros
Organics) in DMF (20 min+10 min). Peptide synthesis was auto-
matically performed at discrete spots using 9-fluorenyl-methoxycar-
bonyl/tert-butyl (Fmoc/tBu) strategy. For the first cycle, a spotting
volumes of 0.8 μl was used, then increased to 0.9 μl for the
following cycles. After the synthesis and final deprotection an
overnight incubation was performed in a saturated ammonia gas
atmosphere to cleave the peptide amides from the solid support.
Yield and quality of the synthesis were determined using HPLC/MS
analysis on control peptides at different positions on the
membranes. Individual SPOTs (Ø=6 mm) were punched-out from
the membrane, transferred into a round-bottomed sterile 96-well
polypropylene microtiter plate and incubated overnight at room
temperature in 200 μl of sterile water. Peptides concentration was
measured by absorbance at 280 nm using a NanoDrop 1000
spectrophotometer. Control peptides were subjected to analytical
RP-HPLC on a Shim-pack VP-ODS column (120 Å, 150×4.6 mm,
Shimadzu) using a LC2010AHT system (Shimadzu) and 0.1% (v/v)
TFA in H2O (HPLC-grade, VWR, solvent A) and 0.1% (v/v) TFA in
acetonitrile (HPLC-grade, VWR, solvent B). A flow rate of 1 mLmin  1
was applied to a linear gradient of 5% to 70% solvent B in 32.5 min
with an initial 3-min isocratic equilibration. The crude control
peptides were <60% pure. To remove TFA, peptides were re-
suspended in 200 μl of 10 mM HCl and re-lyophilised. Afterwards
the peptide pellets were resuspended in 50 μl of sterile water,
quantified at 214 nm by a Nanodrop 2000. The in house-made
program ConCalc was used to calculate the molar coefficient at
214 nm of each peptide using the values reported.[20] Bac5(1–17),
272, 278, 281 and 291 peptides (�95% pure) were purchased from
NovoPro (China) and their identity was checked by mass spectrom-
etry. These peptides were lyophilized from 10 mM HCl three times
to remove TFA and quantified spectrophotometrically as above.
Bacterial Culture
The following bacterial strains were used: Escherichia coli BW25113,
E. coli BW25113ΔsbmA (JW0368-1, KEIO collection[21]); Acinetobacter
baumannii ATCC 19606, Klebsiella pneumoniae ATCC 700603,
Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus
ATCC 25923. The pathogenic E. coli EURL-VTEC A07, E. coli EURL-
VTEC C07, E. coli SSI-NN14, E. coli EA22, E. coli SSI-OO15 and E. coli
C679-12 strains were generously provided by the European Union
Reference Laboratory for E. coli, Department of Food Safety,
Nutrition and Veterinary Public Health, Istituto Superiore di Sanità,
Rome, Italy. All the strains were grown overnight in Müller-Hinton
broth (MHB, Difco) at 37 °C, with shaking (140 rpm). The day after,
the overnight bacterial cultures were diluted approx. 1 :40 in fresh
MHB and incubated at 37 °C with shaking (140 rpm) until an
OD600nm of �0.3 was reached. E. coli BW25113ΔsbmA was grown in
the presence of 50 μgmL  1 kanamycin.
Minimum Inhibitory Concentration (MIC) Determination
Peptides were diluted in 100 μL of MHB to the concentration of
128 μM, dispensed in the first wells of a 96-wells microtiter plate
(round-bottom) and serially two-fold diluted with MHB into
successive wells in a final volume of 50 μl. Subsequently, 50 μL of a
bacterial suspension (5×105 CFUmL  1) were added to each well,
halving the final concentration of bacteria and peptides. Bacteria
were added to MHB only as bacterial growth-control, whereas
100 μl of MHB were used to check the medium sterility. The plate
was incubated overnight at 37 °C (�18 hours) and sealed with
parafilm to minimise evaporation. The MIC was calculated as the
first clear well without bacterial growth. If barely detectable growth
was present, the OD600nm of the plate was measured by a multiplate
reader Tecan (software Sunrise). The MIC was then calculated as the
well whose OD620 was�1% of that of the untreated growth
control.
Cytotoxicity Assay
The tetrazolium salts test (MTT) was used. Cells of the human line
of B lymphocytes precursors MEC-1 were exposed to peptides and,
as a control, to sterile water. RPMI (Sigma)+10% Fetal Bovine
Serum (Sigma)+2 mM Glutamine+100 UmL  1 penicillin+
100 μgmL  1 streptomycin was used as growth medium. Serial two-
fold dilutions of the peptides were prepared in a 96- flat-bottom
microtiter plate (Euroclone) in a final volume of 50 μL of cell growth
medium. Cells were counted using a Bürker chamber, then 50 μL of
medium containing 105 cells were added to each well, to reach a
final volume of 100 μL. Sterile water instead of peptides was used
as a control. Cells were incubated for 20 hours at 37 °C and 5% CO2.
25 μL of a sterile MTT solution (Sigma) were the added to each well
to the final concentration of 1 mgmL  1 in PBS. Following 4 hours of
incubation in the dark at 37 °C under 5% CO2, 100 μL of 10%w/v
Igepal (Sigma- Aldrich) in 10 mM HCl were added to each well. The
plate was incubated overnight at 37 °C then the OD570nm of the
wells was measured using a plate-reader spectrophotometer Nano-
quant infinite M200pro (Tecan). To calculate cytotoxicity, the value
of OD570nm of the treated samples was compared with that of the
untreated control.
Assessment of Bacterial Membrane Integrity
The bacterial cell integrity was controlled evaluating the propidium
iodide (PI) uptake by flow-cytometry on a Cytomics FC 500
(Beckman-Coulter). 104 bacterial cells were acquired for each
measurement. Mid-log phase E. coli BW25113 cultures diluted to
106 CFUmL  1 in MHB were exposed for 30 min to 4 μM and 16 μM
peptides at 37 °C in the presence of 10 μgmL  1 PI. Membrane
permeabilization was calculated as the % PI-positive cells, and
membrane damage measuring the mean fluorescence intensity
(MFI). An untreated control received sterile water instead of
peptides. By contrast, bacteria were treated with 1 μM colistin as a
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permeabilizing control. Data are reported as the average �
standard deviation.
In vitro Transcription/Translation Assay
E. coli lysate-based transcription-translation coupled assays (RTS100,
Biotech Rabbit) were performed as described previously.[7c,8a,b] 6 μL
reactions, with or without peptide were mixed according to the
manufacturer’s instructions and incubated for 1 h at 30 °C with
shaking (750 rpm). The reaction was then stopped by adding 5 μL
kanamycin (50 μgmL  1). All samples were diluted with 40 μL of
Luciferase assays substrate (Promega) into a white 96-well chimney
flat bottom microtiter plate (Greiner). The luminescence was then
measured using a Tecan Infinite M200 plate reader. The relative
values were determined by defining the luminescence value of the
sample without inhibitor as 100%. All the experiments were
performed as independent triplicates.
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